Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Hiromitsu Akabane"'
Autor:
Kazuyuki Tanaka, Hiroki Tanabe, Hiroki Sato, Chisato Ishikawa, Mitsuru Goto, Naoyuki Yanagida, Hiromitsu Akabane, Shiro Yokohama, Kimiharu Hasegawa, Yohei Kitano, Yuya Sugiyama, Kyoko Uehara, Yu Kobayashi, Yuki Murakami, Takehito Kunogi, Takahiro Sasaki, Keitaro Takahashi, Katsuyoshi Ando, Nobuhiro Ueno, Shin Kashima, Kentaro Moriichi, Keisuke Sato, Sayaka Yuzawa, Mishie Tanino, Masaki Taruiishi, Yasuo Sumi, Yusuke Mizukami, Mikihiro Fujiya, Toshikatsu Okumura
Publikováno v:
Cancer Medicine, Vol 11, Iss 2, Pp 406-416 (2022)
Abstract Background Chemotherapy for advanced gastric cancer is recommended in the guidelines; however, later‐line treatment remains controversial. Since immune checkpoint inhibitors have been used for the treatment of various malignancies, trials
Externí odkaz:
https://doaj.org/article/daf65b9ccb9641848e42f40a39ed3b32
Autor:
Hiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Shoichiro Ohtani, Masahiro Kashiwaba, Naruto Taira, Tatsuya Toyama, Tomomi Fujisawa, Norikazu Masuda, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
Publikováno v:
Breast Cancer Research and Treatment. 199:231-241
Purpose Neoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This phase III trial evaluated the prognosis of EBC patients treated with/without chemotherapy (CT) follo
Autor:
Hiroji Iwata, Tatsuya Toyama, Naruto Taira, Norikazu Masuda, Yutaka Yamamoto, Tomomi Fujisawa, Shoichiro Ohtani, Masahiro Kashiwaba, Takehiko Sakai, Yoshie Hasegawa, Rikiya Nakamura, Hiromitsu Akabane, Yukiko Shibahara, Hironobu Sasano, Takuhiro Yamaguchi
Publikováno v:
Cancer Research. 82:PD13-09
Background: NET is one of option in postmenopausal PBC with ER+ and molecular signature is useful tool to determine with/without CT after surgery. We presented a relationship between molecular signature and response of NET in this study cohort (BCRT;
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 82:1588-1593
Autor:
Yoichi Naito, Rikiya Nakamura, Naoto Kondo, Yuichiro Kikawa, Hideki Maeda, Hiromitsu Akabane, Yasuaki Sagara, Tomohiko Aihara, Isao Yokota, Hirofumi Mukai
PurposeThe bone scan index (BSI) describes the tumor burden in bones as a percent of the total skeletal mass based on reference skeletal masses by bone scintigraphies. We conducted a prospective observational study to investigate the utility of BSI f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b31fc9981776151d6949c85235aead99
https://doi.org/10.21203/rs.3.rs-1295957/v1
https://doi.org/10.21203/rs.3.rs-1295957/v1
Autor:
Takeshi Yamaguchi, Tatsuya Toyama, Yasuaki Sagara, Yukari Uemura, Satoshi Yamashita, Shigeru Imoto, Toshiro Mizuno, Tsutomu Takashima, Hirofumi Mukai, Reiki Nishimura, Tomomi Fujisawa, Shozo Ohsumi, Masato Takahashi, Yasuo Hozumi, Satoshi Fujii, Youngjin Park, Hiromitsu Akabane
Publikováno v:
British Journal of Cancer
Background The effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, has not been evaluated. Methods Patients were randomly assigned to t
Autor:
Masato Takahashi, Eriko Tokunaga, Takanori Watanabe, Tsutomu Takashima, Young-Jin Park, Shozo Ohsumi, Hirofumi Mukai, Yoshiaki Sagara, Tetsuji Kaneko, Yasuo Hozumi, Yasuo Ohashi, Hiromitsu Akabane
Publikováno v:
Cancer Research. 80:P1-21
Background: It is critical that a large proportion of eligible patients should participate in clinical trials. However, recruitment into clinical trials requires informed consent and involves some difficult and complex problems. Therefore, it is impo
Autor:
Hiromitsu Akabane, Sunao Ikeue, Keisuke Satoh, Kenji Yamada, Taiichiro Shibaki, Mitsuhiro Inagaki
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 81:41-47
Autor:
Takahiro Sasaki, Kyoko Uehara, Shiro Yokohama, Shin Kashima, Hiroki Tanabe, Chisato Ishikawa, Mishie Tanino, Masaki Taruiishi, Yuki Murakami, Naoyuki Yanagida, Kentaro Moriichi, Yasuo Sumi, Hiromitsu Akabane, Mitsuru Goto, Katsuyoshi Ando, Mikihiro Fujiya, Sayaka Yuzawa, Yu Kobayashi, Takehito Kunogi, Yuya Sugiyama, Toshikatsu Okumura, Yohei Kitano, Keisuke Sato, Kazuyuki Tanaka, Nobuhiro Ueno, Hiroki Sato, Keitaro Takahashi, Kimiharu Hasegawa, Yusuke Mizukami
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 11, Iss 2, Pp 406-416 (2022)
Cancer Medicine, Vol 11, Iss 2, Pp 406-416 (2022)
Background Chemotherapy for advanced gastric cancer is recommended in the guidelines; however, later‐line treatment remains controversial. Since immune checkpoint inhibitors have been used for the treatment of various malignancies, trials have been
Autor:
Yukari Uemura, Tomomi Fujisawa, Masato Takahashi, Hirofumi Mukai, Takanori Watanabe, Tsutomu Takashima, Takuya Kawahara, Yasuo Hozumi, Youngjin Park, Reiki Nishimura, Hiromitsu Akabane, Yoshiaki Sagara
Publikováno v:
Br J Cancer
Background We have previously demonstrated S-1 is non-inferior to taxane with respect to overall survival as first-line chemotherapy for HER2-negative metastatic breast cancer. We aimed to confirm whether S-1 is also non-inferior to anthracycline-con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1415a4e526628697e8cc411918b16aa5
https://europepmc.org/articles/PMC8548517/
https://europepmc.org/articles/PMC8548517/